Brought to you by:
Humacyte’s ATEV granted FDA Regenerative Medicine Advanced Therapy designation for advanced PAD
Humacyte recently announced it has been granted Regenerative Medicine Advanced Therapy (RMAT) designation from the US Food and Drug Administration (FDA) for its investigational acellular tissue engineered vessel (ATEV), designed to treat patients with advanced peripheral arterial disease (PAD). This…
Smoking cessation remains a ‘ripe target’ for improved medication adherence in carotid disease
New data presented at the 2024 Vascular Annual Meeting (VAM) held June 19–22 in Chicago have revealed poor overall rates of medical therapy adherence in moderate asymptomatic carotid stenosis patients—with smoking cessation representing a “ripe target” for improvement moving forward.…
SVS raises alarm over healthcare consolidation in comments to FTC, DOJ, HHS
The Society for Vascular Surgery (SVS) has submitted comments to the Federal Trade Commission (FTC), the Department of Justice (DOJ) and the Department of Health and Human Services (HHS) in response to a Request for Information (RFI) concerning the consolidation…
Incentives and coaching offer promise for improving supervised exercise therapy completion in claudicants
Study findings were presented during Saturday, June 22’s Plenary Session 7 support current vascular guidelines advocating for effective supervised exercise therapy (SET) prior to offering vascular intervention for patients with intermittent claudication. That is the belief of Colin Cleary, PhD,…
Gore announces first commercial implant of Gore Tag thoracic branch endoprosthesis in Canada
Gore has announced the first commercial use of the Gore Tag thoracic branch endoprosthesis (TBE) in Canada. The news came as Canadian government health authority Health Canada approved the first-of-its-kind endovascular device, which is indicated to treat lesions of the…
VAM 2024: Paper exploring stroke rates in arch TEVAR emerges as winner of Poster Competition
The 2024 Vascular Annual Meeting (VAM) in Chicago showcased emerging talent in vascular surgery through a moderated Poster Competition held over two days of the conference. This event provided a platform for research and recognized excellence among the next generation…
Endovascular CFA treatment associated with increased rate of long-term CFA-specific reintervention, study finds
A recent study suggests that endovascular treatment of the common femoral artery (CFA) is associated with an increased rate of long-term CFA-specific reintervention, regardless of indication. Nicholas Wells, a medical student at Yale School of Medicine in New Haven, USA,…
New data on TAMBE outcomes in complex aortic aneurysms revealed
The US Food and Drug Administration (FDA)-approved Gore Excluder Thoracoabdominal Branch Endoprosthesis (TAMBE) has been shown to be safe and effective at 30 days for the treatment of patients with complex aortic aneurysms involving the visceral aorta. This is according…
Patient selection may explain ‘counterintuitive’ relationship between carotid stenting volume and outcomes in new study
High stroke and death rates relating to carotid stenting in the Pacific Northwest may be driven by the selection of high-risk patients with less than 80% stenosis, and reducing the frequency of stenting in this high-risk group—along with better adherence…
TCAR and endarterectomy both ‘reasonable’ but stenting linked to worse outcomes in kidney disease patients
A study examining outcomes between different carotid revascularisation procedures has concluded that transcarotid artery revascularisation (TCAR) and carotid endarterectomy (CEA) both represent a “reasonable choice” in severe chronic kidney disease (CKD) and haemodialysis patients—but transfemoral carotid artery stenting (TF-CAS) appears more likely to result…